Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab

(2013) Srinivas Mamidi et al.   Molecular Oncology

Intermediate Monocytes but Not TIE2-Expressing Monocytes Are a Sensitive Diagnostic Indicator for Colorectal Cancer

(2012) Dominic Schauer et al.   PLoS One

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Activity and resistance of trastuzumab according to different clinical settings

(2011) Elda Tagliabue et al.   CANCER TREATMENT REVIEWS

CD16+ monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis

(2011) A.-L. Feng et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Phenotypic Variation in IgG Receptors by Nonclassical FCGR2C Alleles

(2011) J. van der Heijden et al.   JOURNAL OF IMMUNOLOGY

Immunosenescence of Human Natural Killer Cells

(2011) Inmaculada Gayoso et al.   Journal of Innate Immunity

Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials

(2011) Wenjin Yin et al.   PLoS One

Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

(2010) K. Tamura et al.   ANNALS OF ONCOLOGY

Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults

(2010) Sebastian Seidler et al.   BMC IMMUNOLOGY

Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape

(2010) Robert L. Ferris et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential Recruitment of Activating and Inhibitory Fc RII during Phagocytosis

(2010) S. Syam et al.   JOURNAL OF IMMUNOLOGY

Treatment Beyond Progression: Is It Moving from Belief to Evidence?

(2010) R. Yerushalmi et al.   ONCOLOGIST

The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer

(2009) C Horlock et al.   BRITISH JOURNAL OF CANCER

Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing

(2009) Timothy E. Kute et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

(2009) M. Gobert et al.   CANCER RESEARCH

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2009) Neil L. Spector et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

(2009) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells

(2008) Panagiotis Karagiannis et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Relationship between CD107a expression and cytotoxic activity

(2008) Esin Aktas et al.   CELLULAR IMMUNOLOGY

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

(2008) S. Ladoire et al.   CLINICAL CANCER RESEARCH

Selective expression of inhibitory Fcγ receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response

(2008) Lydie Cassard et al.   INTERNATIONAL JOURNAL OF CANCER

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

(2008) Alessandra Beano et al.   Journal of Translational Medicine

Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target

(2008) Sandra D Bohling et al.   MODERN PATHOLOGY